+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Deep Brain Stimulation in Parkinson's Disease Market - Global Forecast to 2030- Product Image
Deep Brain Stimulation in Parkinson's Disease Market - Global Forecast to 2030- Product Image
Sale

Deep Brain Stimulation in Parkinson's Disease Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5532737
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Deep Brain Stimulation in Parkinson’s Disease Market grew from USD 1.23 billion in 2024 to USD 1.43 billion in 2025. It is expected to continue growing at a CAGR of 15.51%, reaching USD 2.93 billion by 2030.

Deep Brain Stimulation (DBS) has emerged as a revolutionary therapy for managing motor symptoms in Parkinson’s disease, offering hope where medication alone falls short. By delivering targeted electrical impulses to specific brain regions, DBS modulates abnormal neural circuits, alleviating tremor, rigidity, and bradykinesia. First approved for Parkinson’s in the late 1990s, DBS has since advanced through refinements in electrode design, stimulation algorithms, and surgical techniques. Today, it stands alongside pharmacological regimens as a cornerstone of multidisciplinary care.

The integration of neuroimaging, intraoperative monitoring, and patient‐specific programming has elevated DBS from an experimental intervention to a standardized treatment option. Clinicians now personalize therapy by selecting between single‐channel and dual‐channel systems, choosing rechargeable or non‐rechargeable implantable pulse generators, and optimizing lead placement. As a result, patients experience improved quality of life and reduced medication burdens.

Looking forward, the field is poised for further breakthroughs. Closed‐loop feedback systems promise adaptive stimulation guided by real‐time biomarker detection. Concurrently, enhancements in directional leads, multisource systems, and minimally invasive delivery techniques are expanding the therapeutic window. This introduction sets the stage for a detailed examination of transformative shifts, tariff impacts, segmentation insights, and strategic imperatives shaping the DBS landscape.

Transformative Shifts in the DBS Treatment Landscape

In recent years, transformative shifts have reshaped the DBS landscape for Parkinson’s disease, driven by technological innovation, evolving clinical protocols, and regulatory momentum. Closed‐loop systems that dynamically adjust stimulation based on neural feedback have moved from concept to clinical trials, promising more precise symptom control and reduced side effects. Directional leads now enable clinicians to steer current toward targeted neuronal populations, minimizing off‐target effects and enhancing therapeutic efficacy.

Multisource systems, which coordinate multiple electrodes and pulse generators, are facilitating tailored stimulation patterns that address complex symptom profiles. At the same time, advancements in imaging and navigation tools have streamlined electrode placement, reducing surgical time and improving accuracy. Regulatory agencies across key markets have responded by approving next‐generation devices and issuing guidelines that support personalized programming and long‐term monitoring.

On the clinical front, interdisciplinary care models have gained traction, integrating neurologists, neurosurgeons, and rehabilitation specialists to optimize patient selection and postoperative management. Telemedicine and remote programming platforms have further democratized access, allowing patients in underserved regions to benefit from expert oversight. These collective shifts underscore a dynamic ecosystem, where innovation, clinical collaboration, and regulatory support converge to redefine the standard of care.

Cumulative Impact of United States Tariffs 2025

The introduction of updated United States tariffs in 2025 has introduced new variables into the DBS supply chain, influencing component sourcing, pricing strategies, and cross-border collaborations. Tariffs targeting imported electrode materials and electronic subassemblies have elevated costs for implantable pulse generators, leads, and remote control devices. In response, manufacturers are reassessing supplier relationships and exploring domestic production to mitigate tariff-induced price pressures.

This recalibration has prompted device developers to rethink design architectures that rely on high-cost imported materials. Some have initiated partnerships with U.S.-based foundries for pulse generator casings and domain-specific chip fabrication, effectively circumventing tariff burdens. At the same time, global supply chains are diversifying, with manufacturers shifting certain production stages to tariff-exempt zones or leveraging free trade agreements to maintain competitive pricing.

Clinicians and health systems are also adapting. Reimbursement frameworks are being updated to reflect increased procedural costs, and value-based contracting models are gaining traction to ensure patient access remains stable. As the landscape adjusts, stakeholders must remain agile, anticipating further tariff revisions and aligning procurement strategies with evolving trade policies.

Key Segmentation Insights

A granular examination of market segments reveals nuanced dynamics that are critical for strategic decision-making. Based on Application, treatment adoption concentrates on advanced Parkinson’s patients who exhibit refractory motor fluctuations, highlighting the need for specialized movement disorder programs. Based on Type of System, the choice between dual-channel and single-channel systems reflects a balance between symptom specificity and cost efficiency, with dual-channel configurations gaining ground for complex presentations. Based on Components, diversity in extensions, implantable pulse generators, leads, and remote control devices underscores modular innovation; specifically, non-rechargeable versus rechargeable generators cater to patient preference and device longevity, while leads differentiated by contact points and material composition impact stimulation precision.

Based on End-User, service delivery spans ambulatory surgical centers, hospitals, and neurology clinics, with chain clinics offering standardized protocols and private clinics driving bespoke care pathways. Based on Age Group, segmentation into elderly adults (61-70 and 71+) and middle-aged adults (40-50 and 51-60) illuminates differential treatment goals, from quality-of-life improvements in older cohorts to functional restoration in the younger bracket. Based on Recommendations, referrals originating from family physicians, geriatric specialists, and neurologists shape patient flow and timing of intervention. Based on Technology, closed-loop systems, directional leads, multisource systems, and open-loop variants-continuous versus scheduled stimulation-define the next frontier of precision therapy. Finally, based on Disease Stage, early-stage candidates benefit from symptom delay strategies while advanced-stage patients prioritize motor complication control.

Key Regional Insights

Regional perspectives highlight distinct adoption patterns and investment priorities. In the Americas, robust reimbursement environments and established neurosurgical infrastructure drive high procedure volumes and rapid uptake of advanced devices. Meanwhile, in Europe, Middle East & Africa, variable regulatory pathways and reimbursement heterogeneity foster localized innovation hubs, with select countries piloting closed-loop and directional lead trials. In the Asia-Pacific, burgeoning healthcare budgets, expanding neurology networks, and increasing patient awareness fuel strong growth momentum, particularly in urban centers where surgical expertise and technological investments converge.

Key Company Insights

The competitive landscape is populated by a mix of legacy medical device giants and nimble specialist innovators. Abbott Laboratories and Medtronic PLC continue to lead through comprehensive DBS portfolios that span rechargeable and non-rechargeable generators. Boston Scientific Corporation and St. Jude Medical, Inc. leverage strong global distribution networks to advance directional lead and multisource system adoption. Meanwhile, focused players such as Aleva Neurotherapeutics SA, NeuroPace Inc., and NeuroSigma, Inc. are pioneering closed-loop and neuromodulation platforms designed for customized stimulation patterns. Nexstim Oy and MicroTransponder Inc. differentiate through proprietary targeting technologies, and Functional Neuromodulation Ltd., General Electric Co., Neuronetics Inc., Renishaw PLC, Siemens AG, Synapse Biomedical Inc., and Beijing Pins Medical Co., Ltd. contribute complementary innovations that span remote programming, materials science, and surgical robotics.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize several strategic actions to navigate emerging opportunities and challenges. First, deepen investment in adaptive stimulation technologies, including closed-loop systems and multisource architectures, to secure differentiation in a maturing market. Second, fortify supply chain resilience by diversifying component sourcing and establishing regional manufacturing hubs that mitigate tariff exposure. Third, expand remote programming and telehealth offerings to extend specialist oversight into underserved areas while enhancing patient engagement and adherence. Fourth, cultivate collaborative relationships with payers to refine value-based reimbursement frameworks that align device performance with clinical outcomes. Finally, accelerate real-world evidence generation through post-market studies and registries to validate safety and efficacy across diverse patient populations.

Conclusion

Deep Brain Stimulation in Parkinson’s disease stands at an inflection point. Technological innovations, shifting trade policies, and evolving clinical paradigms are converging to create new pathways for growth and patient impact. As closed-loop feedback, directional leads, and personalized programming redefine therapeutic boundaries, stakeholders must adapt with agility and precision. Robust segmentation analyses and regional insights provide the blueprint for targeted commercialization, while competitive intelligence underscores the imperative of continuous innovation. Ultimately, those who align strategic investments with emerging clinical needs and regulatory landscapes will lead the next wave of progress in neurostimulation.

Market Segmentation & Coverage

This research report categorizes the Deep Brain Stimulation in Parkinson’s Disease Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Parkinson's Disease
  • Dual-Channel System
  • Single-Channel System
  • Extension{
  • Implantable Pulse Generator
    • Non-Rechargeable Generator
    • Rechargeable Generator
  • Leads
    • Contact Points
    • Materials Used
  • Remote Control Device
  • Ambulatory Surgical Centers
  • Hospitals
  • Neurology Clinics
    • Chain Clinics
    • Private Clinics
  • Elderly Adults
    • 61-70 Years
    • 71 Years And Above
  • Middle-Aged Adults
    • 40-50 Years
    • 51-60 Years
  • Family Physicians
  • Geriatric Specialists
  • Neurologists
  • Closed-Loop Systems
  • Directional Leads
  • Multisource Systems
  • Open-Loop Systems
    • Continuous Stimulation
    • Scheduled Stimulation
  • Advanced Stage Parkinson's
  • Early Stage Parkinson's

This research report categorizes the Deep Brain Stimulation in Parkinson’s Disease Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Deep Brain Stimulation in Parkinson’s Disease Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • Aleva Neurotherapeutics SA
  • Beijing Pins Medical Co.,Ltd.
  • Boston Scientific Corporation
  • Functional Neuromodulation Ltd.
  • General Electric Co.
  • Medtronic PLC
  • MicroTransponder Inc.
  • Neuronetics Inc.
  • NeuroPace Inc.
  • NeuroSigma, Inc.
  • Nexstim Oy
  • Renishaw PLC
  • Siemens AG
  • St. Jude Medical, Inc.
  • Synapse Biomedical Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Deep Brain Stimulation in Parkinson’s Disease Market, by Application
8.1. Introduction
8.2. Parkinson's Disease
9. Deep Brain Stimulation in Parkinson’s Disease Market, by Type Of System
9.1. Introduction
9.2. Dual-Channel System
9.3. Single-Channel System
10. Deep Brain Stimulation in Parkinson’s Disease Market, by Components
10.1. Introduction
10.2. Extension{
10.3. Implantable Pulse Generator
10.3.1. Non-Rechargeable Generator
10.3.2. Rechargeable Generator
10.4. Leads
10.4.1. Contact Points
10.4.2. Materials Used
10.5. Remote Control Device
11. Deep Brain Stimulation in Parkinson’s Disease Market, by End-User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Hospitals
11.4. Neurology Clinics
11.4.1. Chain Clinics
11.4.2. Private Clinics
12. Deep Brain Stimulation in Parkinson’s Disease Market, by Age Group
12.1. Introduction
12.2. Elderly Adults
12.2.1. 61-70 Years
12.2.2. 71 Years And Above
12.3. Middle-Aged Adults
12.3.1. 40-50 Years
12.3.2. 51-60 Years
13. Deep Brain Stimulation in Parkinson’s Disease Market, by Recommendations
13.1. Introduction
13.2. Family Physicians
13.3. Geriatric Specialists
13.4. Neurologists
14. Deep Brain Stimulation in Parkinson’s Disease Market, by Technology
14.1. Introduction
14.2. Closed-Loop Systems
14.3. Directional Leads
14.4. Multisource Systems
14.5. Open-Loop Systems
14.5.1. Continuous Stimulation
14.5.2. Scheduled Stimulation
15. Deep Brain Stimulation in Parkinson’s Disease Market, by Disease Stage
15.1. Introduction
15.2. Advanced Stage Parkinson's
15.3. Early Stage Parkinson's
16. Americas Deep Brain Stimulation in Parkinson’s Disease Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Deep Brain Stimulation in Parkinson’s Disease Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Deep Brain Stimulation in Parkinson’s Disease Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Abbott Laboratories
19.3.2. Aleva Neurotherapeutics SA
19.3.3. Beijing Pins Medical Co.,Ltd.
19.3.4. Boston Scientific Corporation
19.3.5. Functional Neuromodulation Ltd.
19.3.6. General Electric Co.
19.3.7. Medtronic PLC
19.3.8. MicroTransponder Inc.
19.3.9. Neuronetics Inc.
19.3.10. NeuroPace Inc.
19.3.11. NeuroSigma, Inc.
19.3.12. Nexstim Oy
19.3.13. Renishaw PLC
19.3.14. Siemens AG
19.3.15. St. Jude Medical, Inc.
19.3.16. Synapse Biomedical Inc.
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET MULTI-CURRENCY
FIGURE 2. DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET MULTI-LANGUAGE
FIGURE 3. DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECOMMENDATIONS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECOMMENDATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISEASE STAGE, 2024 VS 2030 (%)
FIGURE 22. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DUAL-CHANNEL SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY SINGLE-CHANNEL SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY EXTENSION{, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NON-RECHARGEABLE GENERATOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECHARGEABLE GENERATOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY CONTACT POINTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MATERIALS USED, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REMOTE CONTROL DEVICE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY CHAIN CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEUROLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ELDERLY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY 61-70 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY 71 YEARS AND ABOVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ELDERLY ADULTS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MIDDLE-AGED ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY 40-50 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY 51-60 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MIDDLE-AGED ADULTS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECOMMENDATIONS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY FAMILY PHYSICIANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GERIATRIC SPECIALISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEUROLOGISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY CLOSED-LOOP SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DIRECTIONAL LEADS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MULTISOURCE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY OPEN-LOOP SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY CONTINUOUS STIMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY SCHEDULED STIMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY OPEN-LOOP SYSTEMS, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ADVANCED STAGE PARKINSON'S, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY EARLY STAGE PARKINSON'S, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEUROLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ELDERLY ADULTS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MIDDLE-AGED ADULTS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECOMMENDATIONS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY OPEN-LOOP SYSTEMS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEUROLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ELDERLY ADULTS, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MIDDLE-AGED ADULTS, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECOMMENDATIONS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY OPEN-LOOP SYSTEMS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEUROLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ELDERLY ADULTS, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MIDDLE-AGED ADULTS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECOMMENDATIONS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY OPEN-LOOP SYSTEMS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 96. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2018-2030 (USD MILLION)
TABLE 98. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 99. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, 2018-2030 (USD MILLION)
TABLE 100. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2030 (USD MILLION)
TABLE 101. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEUROLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 103. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 104. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ELDERLY ADULTS, 2018-2030 (USD MILLION)
TABLE 105. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MIDDLE-AGED ADULTS, 2018-2030 (USD MILLION)
TABLE 106. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECOMMENDATIONS, 2018-2030 (USD MILLION)
TABLE 107. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 108. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY OPEN-LOOP SYSTEMS, 2018-2030 (USD MILLION)
TABLE 109. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 110. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2018-2030 (USD MILLION)
TABLE 112. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 113. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, 2018-2030 (USD MILLION)
TABLE 114. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2030 (USD MILLION)
TABLE 115. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEUROLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 117. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 118. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ELDERLY ADULTS, 2018-2030 (USD MILLION)
TABLE 119. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MIDDLE-AGED ADULTS, 2018-2030 (USD MILLION)
TABLE 120. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECOMMENDATIONS, 2018-2030 (USD MILLION)
TABLE 121. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 122. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY OPEN-LOOP SYSTEMS, 2018-2030 (USD MILLION)
TABLE 123. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEUROLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ELDERLY ADULTS, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MIDDLE-AGED ADULTS, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECOMMENDATIONS, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY OPEN-LOOP SYSTEMS, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2030 (USD MILLION)
TABLE 144. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEUROLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 146. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 147. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ELDERLY ADULTS, 2018-2030 (USD MILLION)
TABLE 148. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MIDDLE-AGED ADULTS, 2018-2030 (USD MILLION)
TABLE 149. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECOMMENDATIONS, 2018-2030 (USD MILLION)
TABLE 150. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY OPEN-LOOP SYSTEMS, 2018-2030 (USD MILLION)
TABLE 152. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2018-2030 (USD MILLION)
TABLE 156. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 157. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, 2018-2030 (USD MILLION)
TABLE 158. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2030 (USD MILLION)
TABLE 159. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 160. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEUROLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 161. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 162. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ELDERLY ADULTS, 2018-2030 (USD MILLION)
TABLE 163. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MIDDLE-AGED ADULTS, 2018-2030 (USD MILLION)
TABLE 164. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECOMMENDATIONS, 2018-2030 (USD MILLION)
TABLE 165. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 166. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY OPEN-LOOP SYSTEMS, 2018-2030 (USD MILLION)
TABLE 167. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 168. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2018-2030 (USD MILLION)
TABLE 170. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 171. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, 2018-2030 (USD MILLION)
TABLE 172. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2030 (USD MILLION)
TABLE 173. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEUROLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 175. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 176. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ELDERLY ADULTS, 2018-2030 (USD MILLION)
TABLE 177. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MIDDLE-AGED ADULTS, 2018-2030 (USD MILLION)
TABLE 178. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECOMMENDATIONS, 2018-2030 (USD MILLION)
TABLE 179. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 180. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY OPEN-LOOP SYSTEMS, 2018-2030 (USD MILLION)
TABLE 181. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 182. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2018-2030 (USD MILLION)
TABLE 184. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 185. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, 2018-2030 (USD MILLION)
TABLE 186. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2030 (USD MILLION)
TABLE 187. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEUROLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 189. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 190. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ELDERLY ADULTS, 2018-2030 (USD MILLION)
TABLE 191. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MIDDLE-AGED ADULTS, 2018-2030 (USD MILLION)
TABLE 192. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECOMMENDATIONS, 2018-2030 (USD MILLION)
TABLE 193. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 194. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY OPEN-LOOP SYSTEMS, 2018-2030 (USD MILLION)
TABLE 195. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 196. INDONESIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 197. INDONESIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2018-2030 (USD MILLION)
TABLE 198. INDONESIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 199. INDONESIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, 2018-2030 (USD MILLION)
TABLE 200. INDONESIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2030 (USD MILLION)
TABLE 201. INDONESIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEUROLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 203. INDONESIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 204. INDONESIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ELDERLY ADULTS, 2018-2030 (USD MILLION)
TABLE 205. INDONESIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MIDDLE-AGED ADULTS, 2018-2030 (USD MILLION)
TABLE 206. INDONESIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECOMMENDATIONS, 2018-2030 (USD MILLION)
TABLE 207. INDONESIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 208. INDONESIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY OPEN-LOOP SYSTEMS, 2018-2030 (USD MILLION)
TABLE 209. INDONESIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 210. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2018-2030 (USD MILLION)
TABLE 212. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 213. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, 2018-2030 (USD MILLION)
TABLE 214. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2030 (USD MILLION)
TABLE 215. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 216. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEUROLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 217. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 218. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ELDERLY ADULTS, 2018-2030 (USD MILLION)
TABLE 219. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MIDDLE-AGED ADULTS, 2018-2030 (USD MILLION)
TABLE 220. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECOMMENDATIONS, 2018-2030 (USD MILLION)
TABLE 221. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 222. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY OPEN-LOOP SYSTEMS, 2018-2030 (USD MILLION)
TABLE 223. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 224. MALAYSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. MALAYSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2018-2030 (USD MILLION)
TABLE 226. MALAYSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 227. MALAYSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, 2018-2030 (USD MILLION)
TABLE 228. MALAYSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2030 (USD MILLION)
TABLE 229. MALAYSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 230. MALAYSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEUROLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 231. MALAYSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 232. MALAYSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ELDERLY ADULTS, 2018-2030 (USD MILLION)
TABLE 233. MALAYSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MIDDLE-AGED ADULTS, 2018-2030 (USD MILLION)
TABLE 234. MALAYSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECOMMENDATIONS, 2018-2030 (USD MILLION)
TABLE 235. MALAYSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 236. MALAYSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY OPEN-LOOP SYSTEMS, 2018-2030 (USD MILLION)
TABLE 237. MALAYSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 238. PHILIPPINES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. PHILIPPINES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2018-2030 (USD MILLION)
TABLE 240. PHILIPPINES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 241. PHILIPPINES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, 2018-2030 (USD MILLION)
TABLE 242. PHILIPPINES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2030 (USD MILLION)
TABLE 243. PHILIPPINES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 244. PHILIPPINES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEUROLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 245. PHILIPPINES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 246. PHILIPPINES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ELDERLY ADULTS, 2018-2030 (USD MILLION)
TABLE 247. PHILIPPINES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MIDDLE-AGED ADULTS, 2018-2030 (USD MILLION)
TABLE 248. PHILIPPINES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECOMMENDATIONS, 2018-2030 (USD MILLION)
TABLE 249. PHILIPPINES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 250. PHILIPPINES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY OPEN-LOOP SYSTEMS, 2018-2030 (USD MILLION)
TABLE 251. PHILIPPINES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 252. SINGAPORE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 253. SINGAPORE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2018-2030 (USD MILLION)
TABLE 254. SINGAPORE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 255. SINGAPORE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, 2018-2030 (USD MILLION)
TABLE 256. SINGAPORE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2030 (USD MILLION)
TABLE 257. SINGAPORE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 258. SINGAPORE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY NEUROLOGY CLINICS, 2018-2030 (USD MILLION)
TABLE 259. SINGAPORE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 260. SINGAPORE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY ELDERLY ADULTS, 2018-2030 (USD MILLION)
TABLE 261. SINGAPORE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY MIDDLE-AGED ADULTS, 2018-2030 (USD MILLION)
TABLE 262. SINGAPORE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY RECOMMENDATIONS, 2018-2030 (USD MILLION)
TABLE 263. SINGAPORE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 264. SINGAPORE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY OPEN-LOOP SYSTEMS, 2018-2030 (USD MILLION)
TABLE 265. SINGAPORE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 266. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TYPE OF SYSTEM, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’

Companies Mentioned

  • Abbott Laboratories
  • Aleva Neurotherapeutics SA
  • Beijing Pins Medical Co.,Ltd.
  • Boston Scientific Corporation
  • Functional Neuromodulation Ltd.
  • General Electric Co.
  • Medtronic PLC
  • MicroTransponder Inc.
  • Neuronetics Inc.
  • NeuroPace Inc.
  • NeuroSigma, Inc.
  • Nexstim Oy
  • Renishaw PLC
  • Siemens AG
  • St. Jude Medical, Inc.
  • Synapse Biomedical Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Deep Brain Stimulation In Parkinson's Disease Market Size, Share & Trends Analysis Report By Product (Single-channel, Dual-channel), By End-use (Hospitals, ASCs), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Deep Brain Stimulation In Parkinson's Disease Market Size, Share & Trends Analysis Report By Product (Single-channel, Dual-channel), By End-use (Hospitals, ASCs), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Deep Brain Stimulation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Deep Brain Stimulation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Deep Brain Stimulation Devices Market - Global Forecast to 2030 - Product Image

Deep Brain Stimulation Devices Market - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Deep Brain Stimulation in Parkinson's Disease - Global Strategic Business Report - Product Image

Deep Brain Stimulation in Parkinson's Disease - Global Strategic Business Report

  • Report
  • 274 Pages
  • Global
From
Deep Brain Stimulation Market: Analysis by Product, Application, End Use, Region Size, Trends and Forecast up to 2029 - Product Image

Deep Brain Stimulation Market: Analysis by Product, Application, End Use, Region Size, Trends and Forecast up to 2029

  • Report
  • 153 Pages
  • Global
From

About the Deep Brain Stimulation In Parkinson Disease Market

Deep brain stimulation (DBS) for Parkinson's disease is a therapeutic procedure aimed at managing the symptoms of this neurodegenerative disorder when medication is insufficient or leads to undesirable side effects. This method involves the surgical implantation of electrodes within certain areas of the brain, generating electrical impulses that regulate abnormal impulses. The DBS devices are an integral part of the Central Nervous System (CNS) drugs and devices domain, which encompasses a broad range of therapies for various neurological conditions, including medication, neuromodulation devices, and support services. Within this context, DBS acts as an adjunct to pharmacological treatments, offering an alternative for patients with advanced Parkinson's disease. While CNS drugs typically address the dopaminergic deficits inherent to Parkinson's disease pathophysiology through oral or injectable medications, DBS provides a unique mechanistic approach by directly modulating brain activity and circuits involved in motor control. The procedure is generally reserved for patients exhibiting motor fluctuations and tremors that are not adequately controlled by medication. Several industry players are active in the DBS market for Parkinson's disease. Key companies engaged in the development and provision of DBS systems include Medtronic, Boston Scientific, and Abbott Laboratories. These entities continuously engage in research and development to advance the technology, increase its efficacy, and reduce any associated risks, thereby improving the lives of patients with Parkinson's disease. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.